March 1, 2018 / 10:27 PM / 8 months ago

BRIEF-Reata Announces Top-Line Data From Study Of Patients With Mitochondrial Myopathies

March 1 (Reuters) - Reata Pharmaceuticals Inc:

* REATA ANNOUNCES TOP-LINE DATA FROM THE DOSE-ESCALATION COHORTS OF THE PHASE 2 MOTOR STUDY OF OMAVELOXOLONE IN PATIENTS WITH MITOCHONDRIAL MYOPATHIES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below